Bayesian Capital Management’s KALA BIO KALA Stock Holding History

Bayesian Capital Management’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4	Closed	-$76K	–	563
2020 Q3	$76K	Buy	+4	New	+$91.9K	0.02%	489

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bayesian Capital Management's KALA Position: Q4 2020 in Review

Bayesian Capital Management sold out of KALA BIO (KALA) in Q4 2020, closing a stake of 4 shares — an estimated $76K sold.

Bayesian Capital Management first reported a position in KALA in Q3 2020 and held it in 1 quarter. The position peaked at $76K in Q3 2020. 112 funds tracked by Wall St. Rank hold KALA as of Q4 2020.

Bayesian Capital Management reported no remaining KALA BIO position as of Q4 2020 after selling out during the quarter.
Bayesian Capital Management sold 4 KALA BIO shares in Q4 2020, an estimated $76K.
Bayesian Capital Management first reported a position in KALA BIO in Q3 2020 and held it in 1 quarter.
Bayesian Capital Management's KALA BIO position peaked at $76K in Q3 2020.
112 funds tracked by Wall St. Rank held KALA BIO as of Q4 2020.

Based on Bayesian Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.